Johnson & Johnson in Talks to Buy Ollin for Up to $3.4B
Why is Johnson & Johnson buying Ollin Biosciences?
Johnson & Johnson (JNJ) is in advanced talks to buy Ollin Biosciences for up to $3.4 billion, the Financial Times reported Sunday, aiming to enter retinal disease, though talks could still collapse.
Key numbers
| Maximum deal value | $3.4B$2.2B upfront + $1.2B milestones |
|---|---|
| Upfront cash | $2.2Bpaid to Ollin investors |
| Milestone payments | $1.2Btied to drug progress |
| JNJ close on Nov 13 | $285.75+0.79% (per [3]) |
| $1B+ biotech sales in 2026 | 46prior record: 35 |
What happened
Johnson & Johnson (JNJ) is in advanced talks to buy Ollin Biosciences for up to $3.4 billion, the Financial Times reported Sunday, aiming to enter retinal disease, though talks could still collapse. The offer is $2.2 billion in cash upfront, plus up to $1.2 billion more if Ollin's drug hits set goals (milestones). Ollin is a private company backed by Arch Venture Partners and Mubadala Capital. Its lead drug, OLN324, targets wet age-related macular degeneration and diabetic macular edema, two major causes of vision loss. A deal could be announced as soon as Monday.
Why it matters
Johnson & Johnson has limited exposure to retinal disease today, even though it sells contact lenses, so this deal would open a new medicine market for it. Retinal drugs treat eye conditions that can cause blindness, and demand grows as populations age. The talks also fit a record year for biotech takeovers: 46 companies valued above $1 billion have been sold, beating the old record of 35.
Who this affects
- MarketmixedLow impact
- Biotech investors may see more takeover interest; talks are unconfirmed.
- CompanybullishMedium impact
- J&J gains a late-stage eye drug but pays $2.2B upfront.
- CompetitorsbearishLow impact
- Eye-drug makers like Regeneron could face a new, well-funded rival.
- IndustrybullishMedium impact
- Another big-pharma takeover supports a record year for biotech deals.
Johnson & Johnson vs Regeneron, Roche
How we got here
JNJ shares close at $285.75, up 0.79%, before the deal report.
FT reports J&J is in advanced talks to buy Ollin for up to $3.4B.
A deal could be announced as soon as today, though talks may fail.
What to watch
- Whether J&J and Ollin announce a signed agreement, or talks collapse.2026-11-16
- Progress of OLN324 late-stage trials in wet AMD and diabetic macular edema.H2 2026
Educational content only. Not investment advice.
More briefsAll briefs →
China Retail Sales Slow to 0.4% as Factory Output Misses
Factory output grew 4.8%, below the 5.3% forecast, as the housing slump and cautious shoppers weigh on demand.

Amazon Stock Dips 0.7% After Vulcan Rocket Failure
Amazon (AMZN) fell as a ULA Vulcan rocket, owned by Boeing and Lockheed, lost 40 Leo satellites.
Oil Slips Below $95 Despite Iran Strike on US Base in Bahrain
Brent crude (BZ=F) fell about 1% as forecasts of a supply glut outweighed disputed Hormuz tanker claims.